PrecisCa
S

Current Approach to mTNBC Treatment

By PrecisCa FEATURING Sara A. Hurvitz
September 14, 2022
0 Comments
Login to view comments. Click here to Login

Featured Video

17:04
Novartis Oncology

Discussion on Overall Survival Data Across 3 Phase III Trials in HR+…

Feat. G. Hortobagyi

Featured Video

18:15
Novartis Oncology

CDK4/6 Inhibitor in Postmenopausal Patients With HR+/HER2- mBC: Anal…

Feat. G. Hortobagyi

Related Content

AUTOPLAY
27:39
Breast Health Global Initiative

Metastatic Breast Disease: Treatment and Palliative Care

Feat. A. Eniu
14:37
Cleveland Clinic Taussig Cancer Institute

Hormone Receptor-Postive Advanced Breast Cancer Case 2: Patient with…

Feat. J. Abraham
30:13
Nico Karssemeijer

Deep Learning Systems for Reading Mammograms and Breast Tomosynthesis

19:43
Northwestern Medicine: Chicago Live

Northwestern Live: Live Case - 47 y/o Female with History of Metasta…

Feat. D. Mullady, A. Aadam
16:44
Heather McArthur

Modern Immune Therapy Strategies for Triple-Negative Breast Cancer

19:23
Holy Cross 9th Annual Winter Oncology Symposium

Genetic Testing in Breast and Ovarian Cancer: BRCA1/2 and PARP Inhib…

Feat. D. Guaqueta
13:07
Holy Cross 9th Annual Winter Oncology Symposium

Panel Discussion on Breast Cancer: Promising Drugs and Future Treatm…

Feat. E. Segota, R. L. Mahtani, J. Burgers, M. Abu-Khalaf, B. Moy
07:43
Dana-Farber Cancer Institute

Study of Abemaciclib for Patients with RB-Positive, Triple Negative …

Feat. S. Goel
24:33
Holy Cross 9th Annual Winter Oncology Symposium

Therapeutic Strategies in HER2+ Breast Cancer - Pertuzumab, Neratini…

Feat. B. Moy
12:05
Holy Cross 9th Annual Winter Oncology Symposium

Future Directions in the Targeting of HER2+ Breast Cancer: duration …

Feat. B. Moy
12:44
Holy Cross 9th Annual Winter Oncology Symposium

Emerging Targets in ER Positive Breast Cancer: CDK4/6 inhibitors, Bc…

Feat. M. Abu-Khalaf
10:12
Holy Cross 9th Annual Winter Oncology Symposium

Emerging Targets in HER-2 Negative, TNBC and HER-3 Positive Breast C…

Feat. M. Abu-Khalaf
07:58
Sandra Swain

ASCO 2019 End-of-study Survival Analysis from the Cleopatra Study Sh…

07:58
12th ESO-EONS Masterclass in Oncology Nursing

Triple Negative Disease: Adjuvant Therapy, Hormone Receptor + Diseas…

Feat. O. Pagani
13:36
Baltic and Eurasia Masterclass in Clinical Oncology

Systemic Treatment of TNBC: Staging, BRCAness, Chemotherapy Prognost…

Feat. E. Kharchenko
19:29
2019 Scripps MD Anderson's Oncology Update

ASCO Metastatic HER2+ Breast Review: How Long to Treat Is up To Deba…

Feat. J. Mortimer
10:06
5th Annual Cleveland Breast Cancer Summit: Collaborating For A Cure

NCCN Guidelines Update for TNBC and HER2 Breast Cancer: Immunotherap…

Feat. J. Abraham, W. Gradishar
08:27
5th Annual Cleveland Breast Cancer Summit: Collaborating For A Cure

Therapeutic Options for Systemic Treatment of TNBC & New Data on…

Feat. D. Hicks
15:23
5th Annual Cleveland Breast Cancer Summit: Collaborating For A Cure

Q&A on Clinical Data Behind Changing the Guidelines, Her2+ Testi…

Feat. D. Hicks
18:38
Peter Schmid

Immunotherapy in Metastatic Triple Negative Breast Cancer: IMpassion…